Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria + tetanus + whole-cell pertussis + hepatitis B + haemophilus influenzae type b + inactivated poliovirus
- Development stage
- Phase 2
- Lead developer
- MCM Vaccine Co
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTwP-HepB-Hib-IPV is a hexavalent combination vaccine developed by Bio Farma for the active immunization of infants against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliomyelitis. This specific formulation is notable for its use of whole-cell pertussis (wP) rather than acellular pertussis (aP), which is commonly used in many international markets. The vaccine combines diphtheria and tetanus toxoids, inactivated whole-cell Bordetella pertussis, recombinant hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b capsular polysaccharide conjugated to a carrier protein, and inactivated poliovirus (IPV) types 1, 2, and 3. It is typically administered via intramuscular injection in a multi-dose primary series and is adjuvanted with aluminum phosphate to enhance the immune response.
- Brand names
- Pediarix
- Other names
- DTwP-HepB-Hib-IPV vaccineBio Farma hexavalent vaccineDTwP-Hepatitis B-Hib-IPV (Bio Farma)
02
Targets
Bordetella pertussis antigen-specific B-cell receptors / antibodies / T-cell receptorsBCR-Hib-PRP (Haemophilus influenzae type b PRP-specific B-cell receptor)Hepatitis B surface antigen-specific B-cell receptors / antibodies / T-cell receptorsPRR (Pattern recognition receptors)Poliovirus type 1/2/3 antigen-specific B-cell receptors / antibodies / T-cell receptorsHBsAg (Hepatitis B surface antigen)PRNP (Cellular Prion Protein)TT (Tetanus toxoid)
Beyond the preview
Go deeper on diphtheria + tetanus + whole-cell pertussis + hepatitis B + haemophilus influenzae type b + inactivated poliovirus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria + tetanus + whole-cell pertussis + hepatitis B + haemophilus influenzae type b + inactivated poliovirus.